United States

People: AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

24 Mar 2017
Change (% chg)

$0.40 (+1.85%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Thomas, Frank 

Mr. Frank E. Thomas is no longer President, Chief Operating Officer of the Company effective April 30, 2017. He was Chief Operating Officer, Executive Vice President of AMAG Pharmaceuticals Inc. He joined in August 2011 as Executive Vice President, Chief Financial Officer and Treasurer and currently serves as Executive Vice President and Chief Operating Officer. From November 2011 to May 2012, he also served as Interim President and Chief Executive Officer. Prior to joining, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., or Molecular Biometrics, a commercial stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., or Critical Therapeutics, a public biopharmaceutical company, from 2004 to 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the Board of Directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas was the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc. Since 2007, he has been a member of the Board of Directors of the Massachusetts Biotechnology Council. Mr. Thomas holds a B.B.A. in Business Administration from the University of Michigan, Ann Arbor.

Basic Compensation

Total Annual Compensation, USD 757,131
Restricted Stock Awards, USD 533,258
Long-Term Incentive Plans, USD --
All Other, USD 310,006
Fiscal Year Total, USD 1,600,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --